NO20074332L - Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser - Google Patents
Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelserInfo
- Publication number
- NO20074332L NO20074332L NO20074332A NO20074332A NO20074332L NO 20074332 L NO20074332 L NO 20074332L NO 20074332 A NO20074332 A NO 20074332A NO 20074332 A NO20074332 A NO 20074332A NO 20074332 L NO20074332 L NO 20074332L
- Authority
- NO
- Norway
- Prior art keywords
- nervous system
- central nervous
- preparation
- treatment
- system disorders
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Den foreliggende oppfinnelse tilveiebringer en fremgangsmåte og et preparat for behandling av en sentralnervesystemforstyrrelse hos et pattedyrindivid, som omfatter administrering av en effektiv mengde av en 11-deoksyprostaglandinforbindelse til et individ som trenger det. Oppfinnelsen tilveiebringer også nye 11-deoksyprostaglandinforbindelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64700805P | 2005-01-27 | 2005-01-27 | |
PCT/JP2006/301704 WO2006080549A2 (en) | 2005-01-27 | 2006-01-26 | Method and composition for treating central nervous system disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20074332L true NO20074332L (no) | 2007-10-17 |
NO340257B1 NO340257B1 (no) | 2017-03-27 |
Family
ID=36740907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074332A NO340257B1 (no) | 2005-01-27 | 2007-08-24 | 11-deoksyprostaglandinforbindelse og anvendelse derav til fremstilling av et preparat for behandling av en sentralnervesystemforstyrrelse hos et pattedyrindivid |
Country Status (20)
Country | Link |
---|---|
US (2) | US8202909B2 (no) |
EP (2) | EP1841433B1 (no) |
JP (1) | JP5147404B2 (no) |
KR (1) | KR101354771B1 (no) |
CN (1) | CN101146541B (no) |
AR (1) | AR055846A1 (no) |
AU (1) | AU2006209072B2 (no) |
BR (1) | BRPI0607084A2 (no) |
CA (1) | CA2595898C (no) |
DK (1) | DK1841433T3 (no) |
ES (1) | ES2375082T3 (no) |
HK (1) | HK1118716A1 (no) |
IL (1) | IL184578A (no) |
NO (1) | NO340257B1 (no) |
NZ (1) | NZ556710A (no) |
PL (1) | PL1841433T3 (no) |
PT (1) | PT1841433E (no) |
RU (1) | RU2440338C2 (no) |
TW (1) | TWI384988B (no) |
WO (1) | WO2006080549A2 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
EP2114411A2 (en) * | 2007-02-27 | 2009-11-11 | Sucampo AG | Composition and method for protecting mitochondria |
CN103393618A (zh) * | 2007-07-19 | 2013-11-20 | 株式会社·R-技术上野 | 包含11-脱氧-***素化合物的药物组合物和使该化合物稳定化的方法 |
US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
US9084815B2 (en) | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
AU2010362494B2 (en) | 2010-10-15 | 2015-01-15 | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. | Processes for preparation of lubiprostone |
JP6023082B2 (ja) * | 2011-01-24 | 2016-11-09 | インセプタム リサーチ アンド セラピューティクス,インク. | 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物 |
RU2013151166A (ru) * | 2011-04-19 | 2015-05-27 | Сукампо Аг | Способ модуляции активности цитокинов |
NZ620300A (en) * | 2011-08-05 | 2015-09-25 | Sucampo Ag | Method for treating schizophrenia |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
RU2679443C2 (ru) * | 2014-10-21 | 2019-02-11 | Университат Де Лес Ильес Балеарс | Способ синтеза гидрокситриглицеридов и их применение для профилактики и лечения заболеваний |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120243A (en) | 1970-03-09 | 1968-07-17 | Samuelsson Bengt | Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof |
BE786215A (fr) | 1971-07-14 | 1973-01-15 | American Cyanamid Co | Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation |
ZA764727B (en) * | 1975-09-02 | 1977-07-27 | Upjohn Co | Prostanoic acid derivatives |
SU845774A3 (ru) | 1976-04-20 | 1981-07-07 | Фармиталия Карло Эрба С.П.А. (Фирма) | Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ |
US4131738A (en) * | 1977-07-05 | 1978-12-26 | The Upjohn Company | 6-Hydroxy-PGE1 compounds |
CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
ATE117290T1 (de) | 1990-02-26 | 1995-02-15 | R Tech Ueno Ltd | 15-dehydroxy-16-oxoprostaglandine. |
CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
JPH04187637A (ja) * | 1990-11-21 | 1992-07-06 | Ueno Seiyaku Oyo Kenkyusho:Kk | 記憶改善剤 |
JPH07113012B2 (ja) | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規15−ケト−プロスタグランジン類 |
JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
DK0857718T3 (da) | 1996-06-10 | 2002-12-16 | Sucampo Ag | Endothelinantagonist |
CN1206997C (zh) * | 1997-11-28 | 2005-06-22 | 株式会社·R-技术上野 | 内皮缩血管肽拮抗剂 |
JP3703004B2 (ja) | 1998-07-15 | 2005-10-05 | 小野薬品工業株式会社 | 5−チア−ω−置換フェニル−プロスタグランジンE誘導体 |
AU3713600A (en) * | 1999-03-01 | 2000-09-21 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
NZ521464A (en) * | 2000-03-24 | 2004-09-24 | Sucampo Ag | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
CN1214794C (zh) * | 2003-09-08 | 2005-08-17 | 秦正红 | ***素a1在制备治疗脑缺血性中风疾病的药物中的用途 |
-
2006
- 2006-01-26 CN CN2006800094248A patent/CN101146541B/zh not_active Expired - Fee Related
- 2006-01-26 KR KR1020077019366A patent/KR101354771B1/ko active IP Right Grant
- 2006-01-26 PL PL06712847T patent/PL1841433T3/pl unknown
- 2006-01-26 WO PCT/JP2006/301704 patent/WO2006080549A2/en active Application Filing
- 2006-01-26 DK DK06712847.0T patent/DK1841433T3/da active
- 2006-01-26 PT PT06712847T patent/PT1841433E/pt unknown
- 2006-01-26 JP JP2007535160A patent/JP5147404B2/ja not_active Expired - Fee Related
- 2006-01-26 EP EP06712847A patent/EP1841433B1/en active Active
- 2006-01-26 US US11/339,495 patent/US8202909B2/en not_active Expired - Fee Related
- 2006-01-26 CA CA2595898A patent/CA2595898C/en not_active Expired - Fee Related
- 2006-01-26 NZ NZ556710A patent/NZ556710A/en not_active IP Right Cessation
- 2006-01-26 ES ES06712847T patent/ES2375082T3/es active Active
- 2006-01-26 RU RU2007132081/04A patent/RU2440338C2/ru active
- 2006-01-26 AU AU2006209072A patent/AU2006209072B2/en not_active Ceased
- 2006-01-26 TW TW095103028A patent/TWI384988B/zh not_active IP Right Cessation
- 2006-01-26 BR BRPI0607084-1A patent/BRPI0607084A2/pt not_active Application Discontinuation
- 2006-01-26 EP EP11155203A patent/EP2332545A1/en not_active Withdrawn
- 2006-01-26 AR ARP060100290A patent/AR055846A1/es not_active Application Discontinuation
-
2007
- 2007-07-12 IL IL184578A patent/IL184578A/en active IP Right Grant
- 2007-08-24 NO NO20074332A patent/NO340257B1/no not_active IP Right Cessation
-
2008
- 2008-09-18 HK HK08110344.4A patent/HK1118716A1/xx not_active IP Right Cessation
-
2012
- 2012-05-14 US US13/470,377 patent/US20120225938A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL184578A0 (en) | 2007-10-31 |
TWI384988B (zh) | 2013-02-11 |
US20120225938A1 (en) | 2012-09-06 |
WO2006080549A2 (en) | 2006-08-03 |
BRPI0607084A2 (pt) | 2009-08-04 |
NO340257B1 (no) | 2017-03-27 |
TW200642690A (en) | 2006-12-16 |
NZ556710A (en) | 2010-08-27 |
RU2440338C2 (ru) | 2012-01-20 |
KR20070107065A (ko) | 2007-11-06 |
DK1841433T3 (da) | 2012-01-16 |
PT1841433E (pt) | 2012-02-01 |
JP2008528440A (ja) | 2008-07-31 |
CN101146541B (zh) | 2012-04-11 |
AU2006209072B2 (en) | 2011-02-24 |
JP5147404B2 (ja) | 2013-02-20 |
CA2595898A1 (en) | 2006-08-03 |
IL184578A (en) | 2015-02-26 |
US8202909B2 (en) | 2012-06-19 |
WO2006080549A3 (en) | 2007-07-05 |
RU2007132081A (ru) | 2009-03-10 |
ES2375082T3 (es) | 2012-02-24 |
KR101354771B1 (ko) | 2014-01-22 |
EP1841433B1 (en) | 2011-11-30 |
EP2332545A1 (en) | 2011-06-15 |
PL1841433T3 (pl) | 2012-07-31 |
AR055846A1 (es) | 2007-09-12 |
CA2595898C (en) | 2015-04-28 |
AU2006209072A1 (en) | 2006-08-03 |
CN101146541A (zh) | 2008-03-19 |
HK1118716A1 (en) | 2009-02-20 |
US20060194880A1 (en) | 2006-08-31 |
EP1841433A2 (en) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074332L (no) | Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser | |
MX2020007092A (es) | Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos. | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
EA200900783A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
ATE461923T1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
HRP20050826B1 (hr) | Ciklički inhibitori proteinske tirozin kinaze | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
EA200901486A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
NO20092612L (no) | Forbindelser og metode for kinasemodulering og indikasjoner for dette | |
NO20083220L (no) | Heterocykliske derivater som modulatorer for ionekanaler | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |